Abstract
This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto beta-blockers have been underused in diabetic patients, perhaps because of perceived risks of beta-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded.
Original language | English |
---|---|
Pages (from-to) | 233-242 |
Number of pages | 10 |
Journal | Journal of Clinical Pharmacy and Therapeutics |
Volume | 27 |
Issue number | 4 |
DOIs | |
Publication status | Published - 1 Aug 2002 |
Keywords
- diabetes mellitus
- coronary heart disease
- cardioprotection
- sudden death
- beta-blocker